Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved a combination tablet of dapagliflozin and metformin hydrochloride under an original ANDA from Novadoz Pharmaceuticals LLC.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin's original application for dapagliflozin tablets (generic), enabling market entry for the SGLT2 inhibitor.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s generic dapagliflozin (ANDA 211535) as an original application. The approval makes a generic version of dapagl…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Ascend Laboratories, LLC)
FDA approved the original generic application for dapagliflozin, enabling a generic version of the SGLT2 inhibitor used for type 2 diabetes …
-
FDA approval · 2026-04-06FDA Tentative Approval: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA issued tentative approval for Sun Pharmaceutical's generic dapagliflozin and metformin hydrochloride tablet (ANDA 211491), enabling pote…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-04-06FDA Tentative Approval: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA issued tentative approval for Lupin's generic combination of dapagliflozin and metformin hydrochloride, enabling potential U.S. marketin…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND SAXAGLIPTIN — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for a generic fixed-dose combination of dapagliflozin and saxagliptin, manufactured by Novadoz Pharmac…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Ajanta Pharma USA Inc.)
FDA approved the original application for dapagliflozin generic from Ajanta Pharma USA Inc., making the SGLT2 inhibitor available as a gener…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original application (ANDA) for Dapagliflozin and Metformin Hydrochloride from Aurobindo Pharma Limited, a generic combinat…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Sandoz Inc)
FDA approves Sandoz's generic dapagliflozin under Original Application. The approval makes a generic version available for the same indicati…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved the Original Application (ANDA) for dapagliflozin from Florida Pharmaceutical Products, LLC.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' original application for a generic fixed-dose combination tablet of dapagliflozin and metformin hydroc…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original ANDA for dapagliflozin tablets, a generic SGLT2 inhibitor used to improve glycemic control …
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approves the generic dapagliflozin from Macleods Pharmaceuticals Limited under an Original Abbreviated New Drug Application (ANDA).
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Zydus Lifesciences Limited)
FDA approved the original application for dapagliflozin from Zydus Lifesciences Limited, making a generic SGLT2 inhibitor available for glyc…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original application for a generic dapagliflozin and metformin hydrochloride combination from Macleods Pharmaceuticals Limi…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for dapagliflozin, enabling a generic version of the diabetes medication to rea…
-
EMA approval · 2026-03-30EMA Authorised: Glyxambi (empagliflozin;linagliptin) — Boehringer Ingelheim International GmbH
The EMA authorised Glyxambi, a fixed-dose combination of empagliflozin and linagliptin, for the treatment of Type 2 diabetes mellitus.
-
FDA approval · 2026-03-30FDA Approved: GLIPIZIDE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for glipizide by Actavis Pharma, Inc. under the ANDA pathway, enabling an additional or updated appr…
-
EMA approval · 2026-03-24EMA Authorised: Jardiance (empagliflozin) — Boehringer Ingelheim International GmbH
EMA authorised Jardiance (empagliflozin) in the European Union for type 2 diabetes mellitus, heart failure, and chronic kidney disease, unde…
-
EMA approval · 2026-03-13EMA Authorised: Ebymect (dapagliflozin propanediol monohydrate;metformin hydrochloride) — AstraZeneca AB
The EMA authorised Ebymect, a fixed-dose combination of dapagliflozin propanediol monohydrate and metformin hydrochloride, for Type 2 diabet…
-
EMA approval · 2026-03-13EMA Authorised: Qtern (saxagliptin;dapagliflozin propanediol monohydrate) — Astra Zeneca AB
The European Medicines Agency authorised Qtern, a fixed-dose combination of saxagliptin and dapagliflozin propanediol monohydrate, for type …
-
EMA approval · 2026-03-13EMA Authorised: Xigduo (metformin hydrochloride;dapagliflozin propanediol monohydrate) — AstraZeneca AB
The EMA authorised Xigduo (metformin hydrochloride and dapagliflozin propanediol monohydrate) for the treatment of Type 2 diabetes mellitus.
-
EMA approval · 2026-03-13EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB
The European Medicines Agency authorised Edistride, a dapagliflozin propanediol monohydrate medicine by AstraZeneca, for type 2 diabetes mel…
-
FDA approval · 2026-03-12FDA Approved: SOLIQUA 100/33 — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for SOLIQUA 100/33, a fixed-ratio combination of insulin glargine and lixisenatide, developed by San…